Abnormal cell cycle regulation in malignancy

American Journal of Clinical Pathology

Volumn 112, Issue 1 SUPPL. 1, 1999, Pages

  Dictor, Michael ^a   Ehinger, Mats ^a   Mertens, Fredrik ^a   Åkervall, Jan ^a   Wennerberg, Johan ^a  

^a LUND UNIVERSITY HOSPITAL   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLIN B; CYCLIN DEPENDENT KINASE; CYCLINE; DNA; DNA POLYMERASE; KI 67 ANTIGEN; PHOSPHOPROTEIN PHOSPHATASE; PROTEIN KINASE; PROTEIN P21; REGULATOR PROTEIN; RETINOBLASTOMA PROTEIN;

BREAST CARCINOMA; CELL CYCLE; CHROMOSOME ANALYSIS; FLOW CYTOMETRY; FLUORESCENCE IN SITU HYBRIDIZATION; GENE DELETION; GENE REARRANGEMENT; GLIOMA; GYNECOLOGIC CANCER; HEAD AND NECK CARCINOMA; HUMAN; IMMUNOHISTOCHEMISTRY; LEUKEMIA; LUNG CARCINOMA; LYMPHOMA; MALIGNANT NEOPLASTIC DISEASE; MELANOMA; MULTIVARIATE ANALYSIS; POINT MUTATION; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROGNOSIS; PROSTATE CARCINOMA; PROTEIN PHOSPHORYLATION; PROTO ONCOGENE; REGULATOR GENE; REVIEW; SARCOMA; STOMACH CARCINOMA; TUMOR SUPPRESSOR GENE; UROGENITAL TRACT TUMOR;

CELL CYCLE; CELL CYCLE PROTEINS; COST-BENEFIT ANALYSIS; DNA, NEOPLASM; GENETIC TECHNIQUES; HUMANS; NEOPLASMS; TUMOR MARKERS, BIOLOGICAL;

EID: 0033506770     PISSN: 00029173     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (108)

1. Pardee AB. A restriction point for control of normal animal cell proliferation. Proc Natl Acad Sci U S A. 1974;71:1286-1290.
2. Hartwell LH, Weinert TA. Checkpoints: controls that ensure the order of cell cycle events. Science. 1989;246:629-634.
3. Sherr CJ. Cancer cell cycles. Science. 1996;274:1672-1677.
4. Kaldis P, Russo AA, Chou HS, et al. Human and yeast Cdk-activating kinases (caks) display distinct substrate specificities. Mol Biol Cell. 1998;9:2545-2560.
5. Peter M. The regulation of cyclin-dependent kinase inhibitors (CKIs). Prog Cell Cycle Res. 1997;3:99-108.
6. Lee WH, Bookstein R, Hong F, et al. Human retinoblastoma susceptibility gene: cloning, identification, and sequence. Science. 1987;235:1394-1399.
7. Tao Y, Kassatly RF, Cress WD, et al. Subunit composition determines E2F DNA-binding site specificity. Mol Cell Biol. 1997;17:6994-7007.
8. Hengstschlager M, Hengstschlager-Ottnad E, Pusch O, et al. The role of p16 in the E2F-dependent thymidine kinase regulation. Oncogene. 1996;12:1635-1643.
9. Bresnahan WA, Boldogh I, Ma T, et al. Cyclin E/Cdk2 activity is controlled by different mechanisms in the G0 and G1 phases of the cell cycle. Cell Growth Differ. 1996;7:1283-1290.
10. Mayol X, Grana X. pRB, p107 and p130 as transcriptional regulators: role in cell growth and differentiation. Prog Cell Cycle Res. 1997;3:157-169.
11. King KL, Cidlowski JA. Cell cycle regulation and apoptosis. Annu Rev Physiol. 1998;60:601-617.
12. Zeng Y, Forbes KC, Wu Z, et al. Replication checkpoint requires phosphorylation of the phosphatase Cdc25 by Cds1 or Chk1. Nature. 1998;395:507-510.
13. Furnari B, Rhind N, Russell P. Cdc25 mitotic inducer targeted by Chk1 DNA damage checkpoint kinase. Science. 1997;277:1495-1497.
14. Sanchez Y, Wong C, Thoma RS, et al. Conservation of the Chk1 checkpoint pathway in mammals: linkage of DNA damage to Cdk regulation through Cdc25. Science. 1997;277:1497-1501.
15. Ball KL. p21: structure and functions associated with cyclin-CDK binding. Prog Cell Cycle Res. 1997;3:125-134.
16. Pan ZQ, Reardon JT, Li L, et al. Inhibition of nucleotide excision repair by the cyclin-dependent kinase inhibitor p21. J Biol Chem. 1995;270:2208-2216.
17. Watanabe H, Pan ZQ, Schreiber Agus N, et al. Suppression of cell transformation by the cyclin-dependent kinase inhibitor p57KIP2 requires binding to proliferating cell nuclear antigen. Proc Natl Acad Sci U S A. 1998;95:1392-1397.
18. Weinberg WC, Montana NE, Deng C. Loss of p21CIP1/WAF1 does not recapitulate accelerated malignant conversion caused by p53 loss in experimental skin carcinogenesis. Oncogene. 1997;15:685-690.
19. Serrano M. The tumor suppressor protein p161NK4a. Exp Cell Res. 1997;237:7-13.
20. Flink IL, Oana S, Maitra N, et al. Changes in E2F complexes containing retinoblastoma protein family members and increased cyclin-dependent kinase inhibitor activities during terminal differentiation of cardiomyocytes. J Mol Cell Cardiol. 1998;30:563-578.
21. Chen PL, Riley DJ, Chen Y, et al. Retinoblastoma protein positively regulates terminal adipocyte differentiation through direct interaction with C/EBPs. Genes Dev. 1996;10:2794-2804.
22. Bergh G, Ehinger M, Olofsson T, et al. Altered expression of the retinoblastoma tumor-suppressor gene in leukemic cell lines inhibits induction of differentiation but not G1-accumulation. Blood. 1997;89:2938-2950.
23. Ehinger M, Bergh G, Johnsson E, et al. Tumor suppressor gene p53 can mediate transforming growth factor B1-induced differentiation of leukemic cells independently of activation of the retinoblastoma protein. Cell Growth Differ. 1997;8:1127-1137.
24. Di Cunto F, Topley G, Calautti E, et al. Inhibitory function of p21Cip1/WAF1 in differentiation of primary mouse keratinocytes independent of cell cycle control. Science. 1998;280:1069-1072.
25. Zhou JQ, He H, Tan CK, et al. The small subunit is required for functional interaction of DNA polymerase delta with the proliferating cell nuclear antigen. Nucleic Acids Res. 1997;25:1094-1099.
26. Cayrol C, Knibiehler M, Ducommun B. p21 binding to PCNA causes G1 and G2 cell cycle arrest in p53-deficient cells. Oncogene. 1998;16:311-320.
27. Prosperi E. Multiple roles of the proliferating cell nuclear antigen: DNA replication, repair and cell cycle control. Prog Cell Cycle Res. 1997;3:193-210.
28. van Oijen MG, Medema RH, Slootweg PJ, et al. Positivity of the proliferation marker Ki-67 in noncycling cells. Am J Clin Pathol. 1998;110:24-31.
29. Maelandsmo GM, Holm R, Fodstad O, et al. Cyclin kinase inhibitor p21WAF1/CIP1 in malignant melanoma: reduced expression in metastatic lesions. Am J Pathol. 1996;149:1813-1822.
30. Porter PL, Malone KE, Heagerty PJ, et al. Expression of cell-cycle regulators p27Kip1 and cyclin E, alone and in combination, correlate with survival in young breast cancer patients. Nature Med. 1997;3:222-225.
31. Orlow I, Iavarone A, Crider Miller SJ, et al. Cyclin-dependent kinase inhibitor p57KIP2 in soft tissue sarcomas and Wilms' tumors. Cancer Res. 1996;56:1219-1221.
32. Kamb A, Gruis NA, Weaver Feldhaus J, et al. A cell cycle regulator potentially involved in genesis of many tumor types. Science. 1994;264:436-440.
33. Takeuchi S, Bartram CR, Seriu T, et al. Analysis of a family of cyclin-dependent kinase inhibitors: p15/MTS2/INK4B, p16/MTS1/INK4A, and p18 genes in acute lymphoblastic leukemia of childhood. Blood. 1995;86:755-760.
34. Batova A, Diccianni MB, Yu JC, et al. Frequent and selective methylation of p15 and deletion of both p15 and p16 in T-cell acute lymphoblastic leukemia. Cancer Res. 1997;57:832-836.
35. Drexler HG. Review of alterations of the cyclin-dependent kinase inhibitor INK4 family genes p15, p16, p18 and p19 in human leukemia-lymphoma cells. Leukemia. 1998;12:845-859.
36. Hegi ME, zur Hausen A, Ruedi D, et al. Hemizygous or homozygous deletion of the chromosomal region containing the p16INK4a gene is associated with amplification of the EGF receptor gene in glioblastomas. Int J Cancer. 1997;73:57-63.
37. Lilischkis R, Sarcevic B, Kennedy C, et al. Cancer-associated missense and deletion mutations impair p16INK4 CDK inhibitory activity. Int J Cancer. 1996;66:249-254.
38. Larsen CJ. Contribution of the dual coding capacity of the p16INK4a/MTS1/CDKN2 locus to human malignancies. Prog Cell Cycle Res. 1997;3:109-124.
39. Galaktionov K, Lee AK, Eckstein J, et al. CDC25 phosphatases as potential human oncogenes. Science. 1995;269:1575-1577.
40. Op De Beeck A, Caillet Fauquet P. Viruses and the cell cycle. Prog Cell Cycle Res. 1997;3:1-19.
41. Krynska B, Gordon J, Otte J, et al. Role of cell cycle regulators in tumor formation in transgenic mice expressing the human neurotropic virus, JCV, early protein. J Cell Biochem. 1997;67:223-230.
42. Funk JO, Waga S, Harry JB, et al. Inhibition of CDK activity and PCNA-dependent DNA replication by p21 is blocked by interaction with the HPV-16 E7 oncoprotein. Genes Dev. 1997;11:2090-2100.
43. Nichols GE, Williams ME, Gaffey MJ, et al. Cyclin D1 gene expression in human cervical neoplasia. Mod Pathol. 1996;9:418-425.
44. Cho NH, Kim YT, Kim JW. Correlation between G1 cyclins and HPV in the uterine cervix. Int J Gynecol Pathol. 1997;16:339-347.
45. Mate JL, Ariza A, Roca X, et al. Expression patterns of cyclins D1 and E in condyloma acuminatum in comparison with psoriatic proliferative lesions. J Pathol. 1998;184:83-38.
46. RB expression in human cells and tissues. Appl Immunohistochem. 1996;4:16-24.
47. Tamboli P, Amin MB, Xu HJ, et al. Immunohistochemical expression of retinoblastoma and p53 tumor suppressor genes in prostatic intraepithelial neoplasia: comparison with prostatic adenocarcinoma and benign prostate. Mod Pathol. 1998;11:247-252.
48. Hendricks JB, Wilkinson EJ. Quality control considerations for Ki-67 detection and quantitation in paraffin-embedded tissue. J Cell Biochem 1994;19(suppl):105-110.
49. Shi SR, Imam SA, Young L, et al. Antigen retrieval immunohistochemistry under the influence of pH using monoclonal antibodies. J Histochem Cytochem. 1995;43:193-201.
50. Holt PR, Moss SF, Kapetanakis AM, et al. Is Ki-67 a better proliferative marker in the colon than proliferating cell nuclear antigen? Cancer Epidemiol Biomarkers Prev. 1997;6:131-135.
51. Leong ASY, Milios J, Tang SK. Is immunolocalisation of proliferating cell nuclear antigen (PCNA) in paraffin sections a valid index of cell proliferation? Appl Immunohistochem. 1993;1:127-130.
52. Koduru PR, Zariwala M, Soni M, et al. Deletion of cyclin-dependent kinase 4 inhibitor genes P15 and P16 in non-Hodgkin's lymphoma. Blood. 1995;86:2900-2905.
53. Fung YK, Murphree AL, T'Ang A, et al. Structural evidence for the authenticity of the human retinoblastoma gene. Science. 1987;236:1657-1661.
54. Balazs M, Carroll P, Kerschmann R, et al. Frequent homozygous deletion of cyclin-dependent kinase inhibitor 2 (MTS1, p16) in superficial bladder cancer detected by fluorescence in situ hybridization. Genes Chromosomes Cancer. 1997;19:84-89.
55. Coignet LJ, Schuuring E, Kibbelaar RE, et al. Detection of 11q13 rearrangements in hematologic neoplasias by double-color fluorescence in situ hybridization. Blood. 1996;87:1512-1519.
56. Perry A, Nobori T, Ru N, et al. Detection of p16 gene deletions in gliomas: a comparison of fluorescence in situ hybridization (FISH) versus quantitative PCR. J Neuropathol Exp Neurol. 1997;56:999-1008.
57. DeMuth JP, Jackson CM, Weaver DA, et al. The gene expression index c-myc × E2F-1/p21 is highly predictive of malignant phenotype in human bronchial epithelial cells. Am J Respir Cell Mol Biol. 1998;19:18-24.
58. Battifora H. P53 immunohistochemistry: a word of caution. Hum Pathol. 1994;25:435-437.
59. Zukerberg LR, Yang WI, Gadd M, et al. Cyclin D1 (PRAD1) protein expression in breast cancer: approximately one-third of infiltrating mammary carcinomas show overexpression of the cyclin D1 oncogene. Mod Pathol. 1995;8:560-567.
60. de Boer CJ, Schuuring E, Dreef E, et al. Cyclin D1 protein analysis in the diagnosis of mantle cell lymphoma. Blood. 1995;86:2715-2723.
61. Vasef MA, Medeiros LJ, Koo C, et al. Cyclin D1 immunohistochemical staining is useful in distinguishing mantle cell lymphoma from other low-grade B-cell neoplasms in bone marrow. Am J Clin Pathol. 1997;108:302-307.
62. Nakamura S, Yatabe Y, Kuroda H, et al. Immunostaining of PRAD1/cyclin D1 protein as a marker for the diagnosis of mantle cell lymphoma. Leukemia. 1997;11(suppl 3):536-537.
63. Ott MM, Helbing A, Ott G, et al. Bcl-1 rearrangement and cyclin D1 protein expression in mantle cell lymphoma. J Pathol. 1996;179:238-242.
64. de Boer CJ, van Krieken JH, Schuuring E, et al. Bcl-1/cyclin D1 in malignant lymphoma. Ann Oncol. 1997;8(suppl 2):109-117.
65. Swerdlow SH, Zukerberg LR, Yang WI, et al. The morphologic spectrum of non-Hodgkin's lymphomas with BCL1/ cyclin D1 gene rearrangements. Am J Surg Pathol. 1996;20:627-640.
66. Jares P, Campo E, Pinyol M, et al. Expression of retinoblastoma gene product (pRb) in mantle cell lymphomas: correlation with cyclin D1 (PRAD1/CCND1) mRNA levels and proliferative activity. Am J Pathol. 1996;148:1591-1600.
67. Lai R, Medeiros LJ, Coupland R, et al. Immunohistochemical detection of E2F-1 in non-Hodgkin's lymphomas: a survey of 124 cases. Mod Pathol. 1998;11:457-463.
68. Hall PA, Coates PJ. Assessment of cell proliferation in pathology: What next? Histopathology. 1995;26:105-112.
69. Catzavelos C, Bhattacharya N, Ung YC, et al. Decreased levels of the cell-cycle inhibitor p27Kip1 protein: prognostic implications in primary breast cancer. Nature Med. 1997;3:227-230.
70. Landberg G, Roos G. The cell cycle in breast cancer. APMIS. 1997;105:575-589.
71. Pelosio P, Barbareschi M, Bonoldi E, et al. Clinical significance of cyclin D1 expression in patients with node-positive breast carcinoma treated with adjuvant therapy. Ann Oncol. 1996;7:695-703.
72. van Diest PJ, Michalides RJ, Jannink L, et al. Cyclin D1 expression in invasive breast cancer: correlations and prognostic value. Am J Pathol. 1997;150:705-711.
73. Scott KA, Walker RA. Lack of cyclin E immunoreactivity in non-malignant breast and association with proliferation in breast cancer. Br J Cancer. 1997;76:1288-1292.
74. Catzavelos C, Bhattacharya N, Ung YC, et al. Decreased levels of the cell-cycle inhibitor p27Kip1 protein: prognostic implications in primary breast cancer. Nature Med. 1997;3:227-230.
75. Tan P, Cady B, Wanner M, et al. The cell cycle inhibitor p27 is an independent prognostic marker in small (T1a,b) invasive breast carcinomas. Cancer Res. 1997;57:1259-1263.
76. McIntosh GG, Anderson JJ, Milton I et al. Determination of the prognostic value of cyclin D1 overexpression in breast cancer. Oncogene. 1995;11:885-891.
77. Dettmar P, Harbeck N, Thomssen C, et al. Prognostic impact of proliferation-associated factors MIB1 (Ki-67) and S-phase in node-negative breast cancer. Br J Cancer. 1997;75:1525-1533.
78. Cote RJ, Shi Y, Groshen S, et al. Association of p27Kip1 levels with recurrence and survival in patients with stage C prostate carcinoma. J Natl Cancer Inst. 1998;90:916-920.
79. Yang RM, Naitoh J, Murphy M, et al. Low p27 expression predicts poor disease-free survival in patients with prostate cancer. J Urol. 1998;159:941-945.
80. Raybaud Diogene H, Fortin A, Morency R, et al. Markers of radioresistance in squamous cell carcinomas of the head and neck: a clinicopathologic and immunohistochemical study. J Clin Oncol. 1997;15:1030-1038.
81. Hirvikoski P, Kumpulainen E, Virtaniemi J, et al. p53 expression and cell proliferation as prognostic factors in laryngeal squamous cell carcinoma. J Clin Oncol. 1997;15:3111-3120.
82. Kyomoto R, Kumazawa H, Toda Y, et al. Cyclin-D1-gene amplification is a more potent prognostic factor than its protein over-expression in human head-and-neck squamous-cell carcinoma. Int J Cancer. 1997;74:576-581.
83. Akervall J, Jin Y, Wennerberg J, et al. Chromosomal abnormalities involving 11q13 are associated with poor prognosis in squamous cell carcinoma of the head and neck. Cancer. 1995;76:453-459.
84. Akervall J, Michalides RJAM, Mineta H, et al. Amplification of cyclin D1 in squamous cell carcinoma of the head and neck and the prognostic value of chromosomal abnormalities and cyclin D1 overexpression. Cancer. 1997;79:380-389.
85. Kawana H, Tamaru J, Tanaka T, et al. Role of p27Kip1 and cyclin-dependent kinase 2 in the proliferation of non-small cell lung cancer. Am J Pathol. 1998;153:505-513.
86. Volm M, Koomagi R, Rittgen W. Clinical implications of cyclins, cyclin-dependent kinases, RB and E2F1 in squamous-cell lung carcinoma. Int J Cancer. 1998;79:294-299.
87. Harpole DH, Richards WG, Herndon JE, et al. Angiogenesis and molecular biologic substaging in patients with stage I non-small cell lung cancer. Ann Thorac Surg. 1996;61:1470-1476.
88. Xu HJ, Quinlan DC, Davidson AG, et al. Altered retinoblastoma protein expression and prognosis in early-stage non-small-cell lung carcinoma. J Natl Cancer Inst. 1994;86:695-699.
89. Kinoshita I, Dosaka Akita H, Mishina T, et al. Altered p16INK4 and retinoblastoma protein status in non-small cell lung cancer: potential synergistic effect with altered p53 protein on proliferative activity. Cancer Res. 1996;56:5557-5562.
90. Victorzon M, Roberts PJ, Haglund C, et al. Ki-67 immunoreactivity, ploidy and S-phase fraction as prognostic factors in patients with gastric carcinoma. Oncology. 1996;53:182-191.
91. Sakaguchi T, Watanabe A, Sawada H, et al. Prognostic value of cyclin E and p53 expression in gastric carcinoma. Cancer. 1998;82:1238-1243.
92. Lu X, Toki T, Konishi I, et al. Expression of p21WAF1/CIP1 in adenocarcinoma of the uterine cervix: a possible immunohistochemical marker of a favorable prognosis. Cancer. 1998;82:2409-2417.
93. Cordon Cardo C, Zhang ZF, Dalbagni G, et al. Cooperative effects of p53 and pRB alterations in primary superficial bladder tumors. Cancer Res. 1997;57:1217-1221.
94. Yatabe Y, Nakamura S, Seto M, et al. Clinicopathologic study of PRAD1/cyclin D1 overexpressing lymphoma with special reference to mantle cell lymphoma: a distinct molecular pathologic entity. Am J Surg Pathol. 1996;20:1110-1122.
95. Coupland SE, Krause L, Delecluse HJ, et al. Lymphoproliferative lesions of the ocular adnexa: analysis of 112 cases. Ophthalmology. 1998;105:1430-1441.
96. Fizzotti M, Cimino G, Pisegna S, et al. Detection of homozygous deletions of the cyclin-dependent kinase 4 inhibitor (p16) gene in acute lymphoblastic leukemia and association with adverse prognostic features. Blood. 1995;85:2685-2690.
97. Ramsay JA, From L, Iscoe NA, et al. MIB-1 proliferative activity is a significant prognostic factor in primary thick cutaneous melanomas. J Invest Dermatol. 1995;105:22-26.
98. Reddy VB, Gattuso P, Aranha G, et al. Cell proliferation markers in predicting metastases in malignant melanoma. J Cutan Pathol. 1995;22:248-251.
99. Monzon J, Liu L, Brill H, et al. CDKN2A mutations in multiple primary melanomas. N Engl J Med. 1998;338:879-887.
100. Lilischkis R, Sarcevic B, Kennedy C, et al. Cancer-associated missense and deletion mutations impair p16INK4 CDK inhibitory activity. Int J Cancer. 1996;66:249-254.
101. Flores JF, Walker GJ, Glendening JM, et al. Loss of the p16INK4a and p15INK4b genes, as well as neighboring 9p21 markers, in sporadic melanoma. Cancer Res. 1996;56:5023-5032.
102. Glendening JM, Flores JF, Walker GJ, et al. Homozygous loss of the p15INK4B gene (and not the p16INK4 gene) during tumor progression in a sporadic melanoma patient. Cancer Res. 1995;55:5531-5535.
103. Reed JA, Loganzo F, Shea CR, et al. Loss of expression of the p16/cyclin-dependent kinase inhibitor 2 tumor suppressor gene in melanocytic lesions correlates with invasive stage of tumor progression. Cancer Res. 1995;55:2713-2718.
104. Talve L, Sauroja I, Collan Y, et al. Loss of expression of the p16INK4/CDKN2 gene in cutaneous malignant melanoma correlates with tumor cell proliferation and invasive stage. Int J Cancer. 1997;74:255-259.
105. Saenz Santamaria MC, McNutt NS, Shea CR. Immunohistochemical expression of retinoblastoma protein in cutaneous melanomas. Br J Dermatol. 1995;133:890-895.
106. McKeever PE. Insights about brain tumors gained through immunohistochemistry and in situ hybridization of nuclear and phenotypic markers. J Histochem Cytochem. 1998;46:585-594.
107. Rautiainen E, Haapasalo H, Sallinen P, et al. Histone mRNA in-situ hybridization in astrocytomas: a comparison with PCNA, MIB-1 and mitoses in paraffin-embedded material. Histopathology. 1998;32:43-50.
108. Levine EA, Holzmayer T, Bacus S, et al. Evaluation of newer prognostic markers for adult soft tissue sarcomas. J Clin Oncol. 1997;15:3249-3257.